Figure 2. Tail vein injection of rAAV induces liver injury, but not hepatic necroptosis, in mice with only hyperglycemia or obesity.

• A
  Schematic of the hyperglycemic mouse model construction by streptozotocin (STZ) and the experimental design for the contribution of hyperglycemia to the liver injury and hepatic necroptosis induced by rAAV injection.
• B, C
  Body weight (B) and blood glucose levels (C) were measured 6 weeks later, after injection once a day for 5 consecutive days with vehicle (Veh) or streptozotocin (STZ). n = 6–19 for each group.
• D–F
  Two months after a single injection of rAAV, hyperglycemic mice induced by streptozotocin showed similar body weight (D), blood glucose levels (F) and increased liver weight (E) compared with those mice injected with PBS. n = 9–10.
• G, H
  Serum ALT (G) and AST (H) activities of mice in (D).
• I
  Liver images, H&E staining of liver sections and the incidence of hepatic necroptosis for mice in (D).
• J
  The hepatic p‐MLKL level of mice in (D).
• K
  Schematic of the obese mouse model construction induced by high‐fat diet (HFD) and the experimental design for the contribution of obesity to the liver injury and hepatic necroptosis induced by rAAV injection.
• L–N
  Body weight (L), fat mass (M) and blood glucose levels (N) of RHH (Resistance to HFD‐induced Hyperglycemia) mice fed with HFD for 15 weeks. n = 6–12.
• O–Q
  Body weight (O), liver weight (P) and blood glucose levels (Q) of obese and euglycemic mice in (L) after a single injection of PBS or rAAV for 2 months. n = 6.
• R, S
  Serum ALT (R) and AST (S) activities of mice in (O).
• T
  Liver images, H&E staining of liver sections and incidence of hepatic necroptosis for mice in (O).
• U
  The hepatic p‐MLKL level of mice in (O).

Data information: In (B–H, J, L–S, U), data are presented as mean ± SD. Student's t‐test.

Source data are available online for this figure.